A new decade has started with the emergence of a novel zoonotic coronavirus, now termed COVID-19, and also known as 2019-nCoV or severe acute respiratory syndrome coronavirus (SARS)-CoV-2 ([@b0120]). Originating in December 2019 in Wuhan, Hubei province, China, with a cluster of patients presenting with pneumonia, COVID-19 has quickly spread not only throughout China, but also throughout the world. As of March 11, 2020, with nearly 125,000 cases and more than 4000 fatalities in 118 countries and territories, COVID-19 has been declared as a pandemic by the World Health Organisation (WHO) ([@b0095], March 11).

1. Who is (not) getting sick and why is this important {#s0005}
======================================================

Of the six previously known coronavirus species, only two other strains -- SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) -- are zoonotic in origin and have been associated with high risk of severe outcomes and mortality, estimated at case-fatality ratio of approximately 11% and 34%, respectively ([@b0080], [@b0085]). Similar to SARS-CoV and MERS-CoV, COVID-19 causes respiratory symptoms that are often severe, with current estimates of case-fatality ratio of 3%-4%, although lower estimates should be considered as more global information comes into light ([@b0100]). While the epidemiology of COVID-19 still unravels and much remains to be learnt, what already appears to be unusual in the case of this and other coronaviruses, is the population at risk. While the most vulnerable population to suffer severe outcomes of respiratory viruses other than coronaviruses are typically older adults, people suffering from chronic medical conditions, and children, in the case of COVID-19 there have so far been no fatalities in children aged 0--9 years of age in China. The disease incidence in children also seems to be lower than in the rest of the population; estimated at 2.4% of all reported cases in people under the age of 18, according to the WHO-China Joint Mission report based on 55,924 laboratory-confirmed cases ([@b0090]). Preliminary statistics from Italy's outbreak of COVID-19, currently the second most affected country outside of China with the highest case-fatality ratio to date of approximately 7%, similarly suggest children are not likely to be at high risk of severe disease ([@b0025]). It appears that COVID-19 infections in children have occurred during the early stages of the pandemic ([@b0035]), but they are reported with less frequency and children do not become as sick.

Although the current pandemic is arguably too new to have produced reliable statistics on population demographics on the world stage, the emerging pattern of resilience to severe outcomes of COVID-19 in children is puzzling considering what we know of other viruses, such as influenza and measles. In the case of influenza, children aged \<5 years are more likely to suffer severe outcomes of both seasonal and pandemic influenza ([@b0070]). Unvaccinated young children are also at highest risk of measles and its severe outcomes, including death ([@b0040]). However, SARS-CoV, MERS-CoV, and now COVID-19 are strikingly less common and less severe in children than in adults ([@b0125]). It is likely that a milder representation of the disease in young children results in decreased reporting and testing, thus leading to under-sampling and the possibility that disease incidence is similar in children to adults ([@b0020]). However, this potential under-sampling in itself points to a decreased illness severity and an overall resilience to the disease in children.

Several reasons have been proposed to try and explain this resilience, one of which is a potential for certain immunity due to the commonality of other human coronaviruses in children ([@b0115]). This reasoning, however, does not explain why the elderly who are also at high risk of infection with human coronaviruses, are not immune. Another potential reason for decreased severity of the disease in children is that pre-existing chronic medical conditions such as cardiovascular diseases may predispose adults to more severe outcomes ([@b0030], [@b0110]). In this regard, angiotensin-converting enzyme 2 (ACE2) that plays role in cardiovascular disease, has been identified as a functional receptor of SARS-CoV and SARS-CoV-2 ([@b0105]), and its potential immaturity in children has been proposed to underlie the reduced disease severity ([@b0020]), but there is currently no supporting evidence to substantiate this claim. There is also a possibility that differences in the maturity of the immune system underlie the different immune responses to an infection. As such, activation of the innate immune system in the early phase of SARS-CoV infection has an important role in the control viral replication ([@b0010]). In the elderly, the innate immune system is less efficient and its ability to respond to infections is diminished, resulting in greater vulnerability of older adults to severe outcomes of infectious diseases ([@b0005]). It is thus plausible that the immune system in the young is more effective in responding to COVID-19, reducing its severity. However, neither of these possibilities really explain why children seem relatively immune (or at least resilient) to COVID-19 but not to influenza or measles and this question is essential to answer. This apparent resilience of children to COVID-19 brings up important ideas that are necessary for the research and medical communities to properly address, and not only in relation to the current pandemic. One is that responses to disease are heterogeneous within a population. Two is that we should be exploiting the causes of this heterogeneity to help patients recover more quickly.

2. One size does not fit all {#s0010}
============================

The idea that responses to disease are heterogeneous within a population is well-acknowledged in the epidemiological community. However, is not one that is particularly well integrated in basic biomedical science research. For decades, if not centuries now, fundamental science has worked with the broad assumption that male mouse and rat models of young-adult age in the absence of a life history of neuroimmune challenge ([@b0055]) are necessary and sufficient to understand all of mammalian physiology.

We also routinely work with how a treatment affects the mean response of a population. Admittedly, there are numerous road blocks to approaching things differently. There is significant cost in both monetary terms and in time in assessing an outcome in both sexes at various stages of hormonal peaks at multiple ages across the lifespan and on the background of a wealth of life experiences. The logistics of "thinking outside the mean" are also complicated and costly. An individual response well-outside the mean could indicate that this single animal or human patient holds the cure to the next viral outbreak, or could just indicate pipetting error or a random variation that is physiologically meaningless for a workable part of the population. The latter issue indicates a particular importance of rigorous statistical approaches in the analysis of our own scientific work and in the assessment of work by others ([@b0045]). A limited sample-size, for instance, may be insufficient to provide valuable information in some cases, but may shed light on critical details in other circumstances when the sample is inherently limited. With appropriate experimental and statistical controls in place, it is therefore essential to start focusing on individual populations of vulnerability and resilience.

In addition to children, pregnant women also represent a vulnerable population at risk for viral infections, with increased risk of complications in influenza, including the 2009 influenza H1N1 pandemic ([@b0075]), varicella virus, measles and the severe foetal consequences of Zika virus (reviewed in ([@b0060])). Interestingly, and in line with the pattern of COVID-19 producing milder symptoms in children, there is currently no evidence for increased risk of severe outcomes of COVID-19 in pregnant women. We should note, though, that this evidence is based on limited data, while reports from SARS-CoV, MERS-CoV and from other respiratory infections suggest these conclusions are premature and pregnant women could be at risk of a severe course of COVID-19 ([@b0065]). If, however, pregnancy proves to provide some protection from disease severity, it could offer unique opportunities for the development of therapeutic solutions. It would also be essential to see whether COVID-19 during pregnancy has longer-term implications for the offspring, similar to neurodevelopmental impacts of maternal influenza and other infections ([@b0050]).

As mentioned above, the elderly and those suffering from chronic medical conditions are also at high risk of severe disease outcomes, and, as such, the unique characteristics of these populations should always be considered when attempting to extrapolate scientific discoveries and their therapeutic applications. This approach is at the heart of a personalised (individualised) medicine approach, where patients' therapies are targeted based on their genetic differences, along with their unique lifestyles and other environmental factors ([@b0015]). The current COVID-19 pandemic and its epidemiology is yet another reminder there is no 'one size fits all' when it comes to all aspects of scientific research, including experimental design, statistical analyses and therapeutic implications.

3. Conclusions on COVID-19 for the psychoneuroimmunology community {#s0015}
==================================================================

A major focus of the field of psychoneuroimmunology is on understanding disease vulnerability and resilience throughout the lifespan. The emerging epidemiology of COVID-19 indicates distinct effects of age on disease severity. While the global research community is focusing now on finding the ways to halt the spread of the virus and prevent its reoccurrence, this pandemic is an important reminder to all biomedical scientists of the wide implications their research may have. To deliver replicable, translatable and robust outcomes, we must consider the heterogeneity of a disease in a population, and to capitalise on both vulnerability and resilience in our search for basic mechanisms and for clinically-relevant health applications.
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